Recall events
/
Event 75247
Event summary
Timeline bucket September 19, 2016
Product types Drug
Classifications Class II and Class III
Statuses Terminated
Recalling firm wording Wells Pharmacy Network, LLC
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
7 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 7
Testosterone 200 mg/Anastrozole 9 mg Pellet, Compounded by: Wells Pharmacy Network
D-0126-2017
Recall number D-0126-2017
Initiated September 19, 2016
Classification Class II
Status Terminated
Quantity 690 pellets
App-derived interpretation
Potency or specification failure
reason.potency_specification_failure · v1.0.0
Superpotent
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Superpotent and Subpotent drugs
Code information BUD: 10/04/2016, Lot number 04072016@40 BUD: 12/03/2016, Lot number 06162016@2 BUD: 01/07/2017, Lot number CA07112016@4
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[2732]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 7
Testosterone Cholesterol ,100 mg Pellet, Compounded by: Wells Pharmacy Network
D-0127-2017
Recall number D-0127-2017
Initiated September 19, 2016
Classification Class III
Status Terminated
Quantity 1 pellet
App-derived interpretation
Potency or specification failure
reason.potency_specification_failure · v1.0.0
Superpotent
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Superpotent and Subpotent drugs
Code information Lot Number 06072016@5, BUD 12/04/2016
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[2566]
FDA event record
· Exact recall-number query on openFDA
drug · product 3 of 7
Testosterone 60 mg/Anastrazole 4 mg Pellet, Compounded by: Wells Pharmacy Network
D-0128-2017
Recall number D-0128-2017
Initiated September 19, 2016
Classification Class II
Status Terminated
Quantity 358 pellets
App-derived interpretation
Potency or specification failure
reason.potency_specification_failure · v1.0.0
Superpotent
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Superpotent and Subpotent drugs
Code information Lot Number 08012016@2, BUD 01/28/2017
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[2796]
FDA event record
· Exact recall-number query on openFDA
drug · product 4 of 7
Testosterone 12.5 mg Pellet, Compounded by: Wells Pharmacy Network
D-0129-2017
Recall number D-0129-2017
Initiated September 19, 2016
Classification Class III
Status Terminated
Quantity 322 pellets
App-derived interpretation
Potency or specification failure
reason.potency_specification_failure · v1.0.0
Superpotent
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Superpotent and Subpotent drugs
Code information Lot Number 08052016@3, BUD 02/01/2017
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[2714]
FDA event record
· Exact recall-number query on openFDA
drug · product 5 of 7
Estradiol 3 mg Pellet, Compounded by: Wells Pharmacy Network
D-0130-2017
Recall number D-0130-2017
Initiated September 19, 2016
Classification Class III
Status Terminated
Quantity 301 pellets
App-derived interpretation
Potency or specification failure
reason.potency_specification_failure · v1.0.0
Superpotent
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Superpotent and Subpotent drugs
Code information Lot Number 08082016@1, BUD: 02/04/2017
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[3288]
FDA event record
· Exact recall-number query on openFDA
drug · product 6 of 7
Testosterone 200 mg/Anastrazole 20mg Pellet, Compounded by: Wells Pharmacy Network
D-0131-2017
Recall number D-0131-2017
Initiated September 19, 2016
Classification Class II
Status Terminated
Quantity 318 pellets
App-derived interpretation
Potency or specification failure
reason.potency_specification_failure · v1.0.0
Superpotent
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Superpotent and Subpotent drugs
Code information Lot Number 08162016@5, BUD: 02/12/2017
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[2704]
FDA event record
· Exact recall-number query on openFDA
drug · product 7 of 7
Estradiol 12.5 mg Pellet, Compounded by: Wells Pharmacy Network
D-0132-2017
Recall number D-0132-2017
Initiated September 19, 2016
Classification Class III
Status Terminated
Quantity 353 pellets
App-derived interpretation
Potency or specification failure
reason.potency_specification_failure · v1.0.0
Superpotent
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Superpotent and Subpotent drugs
Code information Lot Number 08172016@9, BUD: 02/13/2017
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[3781]
FDA event record
· Exact recall-number query on openFDA
